Product image of Mycophenolatmofetil Ascend (Mycophenolate Mofetil) supplied by GNH India

Mycophenolatmofetil Ascend

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mycophenolatmofetil Ascend (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Ascend, is an antimetabolite presented as an oral tablet for oral administration. It is used to prevent organ transplant rejection and to treat selected autoimmune disorders, including lupus nephritis, by inhibiting lymphocyte proliferation.

GNH India supplies Mycophenolatmofetil Ascend as a licensed, GMP‑qualified, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology units and pharmacy chains worldwide, with support for regulatory documentation and reliable logistics to meet local market needs.

Manufacturer / TM Owner

Ascend Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mycophenolate Mofetil is an antimetabolite immunosuppressant used in conditions where inhibition of lymphocyte activity is required.
  • Organ transplant rejection: helps prevent acute and chronic rejection by suppressing immune response.
  • Lupus nephritis: reduces kidney inflammation and proteinuria in patients with systemic lupus erythematosus.
  • Kidney transplant rejection: used to maintain graft function after kidney transplantation.

How It Works

  • Mycophenolate Mofetil is a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the enzyme responsible for de novo synthesis of guanosine nucleotides. By blocking IMPDH, the drug depletes guanosine pools, which are essential for DNA synthesis in proliferating T‑ and B‑lymphocytes, thereby suppressing their activation and clonal expansion while sparing resting cells. This selective action limits the immune response without markedly affecting other cell types.

Side Effects

Mycophenolate Mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, may lead to dehydration.
  • Headache: transient cranial discomfort.
  • Infections: increased susceptibility to bacterial, viral or fungal infections.
  • Elevated liver enzymes: mild transaminase rise.
  • Vomiting: occasional emesis.
  • Rash: mild skin eruptions.

Serious or Rare Side Effects

  • Bone marrow suppression: anemia, leukopenia, thrombocytopenia.
  • Severe infections: opportunistic infections such as CMV or PCP.
  • Gastrointestinal perforation: rare but life‑threatening.
  • Malignancy risk: increased incidence of lymphoproliferative disorders.
  • Pregnancy loss: teratogenic effects leading to fetal harm.
  • Renal dysfunction: impaired kidney function in rare cases.

Precautions & Warnings

When prescribing Mycophenolate Mofetil, clinicians should observe several safety precautions to minimize risk.

  • Monitor blood counts: regular CBC to detect bone marrow suppression.
  • Assess liver function: periodic LFTs for hepatotoxicity.
  • Screen for infections: evaluate for latent viral infections before initiation.
  • Avoid live vaccines: increased risk of vaccine‑derived infection.
  • Pregnancy contraindication: drug is teratogenic, discontinue before conception.
  • Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Avoid Interactions

Mycophenolate Mofetil interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

  • Antacids containing aluminum or magnesium: reduce absorption of mycophenolate.
  • Azathioprine: additive bone marrow suppression.
  • Strong CYP3A4 inducers (e.g., rifampin): markedly decrease drug levels.

Moderate Interactions (Monitor Closely)

  • Cyclosporine or tacrolimus: may increase mycophenolate exposure, adjust dose.
  • Vaccines: live attenuated vaccines may cause infection.
  • Cholestyramine: can bind and lower drug concentration.

Frequently Asked Questions

Mycophenolatmofetil Ascend contains mycophenolate mofetil, an antimetabolite immunosuppressant prescribed to prevent organ transplant rejection and to treat certain autoimmune conditions such as lupus nephritis by limiting lymphocyte proliferation.

Mycophenolate mofetil selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for de novo guanosine nucleotide synthesis. This blocks DNA synthesis in rapidly dividing T‑ and B‑lymphocytes, suppressing their activation while sparing most other cells.

The appropriate dose is individualized by the prescribing clinician based on the patient’s indication, body weight, renal and hepatic function, and concomitant therapies. Dosage regimens are not standardized and must follow the prescriber’s order.

Mycophenolate mofetil is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It is contraindicated in pregnancy and should be discontinued before conception. Breastfeeding is not recommended as the drug is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Compared with calcineurin inhibitors such as cyclosporine, mycophenolate mofetil offers a different mechanism—IMPDH inhibition—resulting in less nephrotoxicity but a higher risk of bone‑marrow suppression and gastrointestinal upset. Choice of therapy depends on the transplant protocol, patient tolerance and comorbidities.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original container, protect from moisture and direct sunlight, and avoid exposure to extreme heat or humidity to maintain product stability.

Mycophenolatmofetil Ascend is supplied as an oral tablet taken by mouth. The tablet should be swallowed whole with water, usually twice daily, unless the prescriber provides a different schedule. Food may be taken with the dose, but patients should follow the specific instructions of their healthcare provider.

Serious adverse events include bone‑marrow suppression (anemia, leukopenia, thrombocytopenia), severe opportunistic infections (e.g., CMV, PCP), gastrointestinal perforation, and increased risk of certain malignancies. Patients should be monitored regularly for blood counts, infection signs and liver function.

The drug is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate or any component of the formulation, and patients with severe, uncontrolled infections. Caution is also advised for those with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT